Ocular Hypertension - Pipeline Insight, 2021

SKU ID :DEL-17687658 | Published Date: 15-Mar-2021 | No. of pages: 60
Introduction Executive Summary Ocular Hypertension: Overview • Causes • Mechanism of Action • Signs and Symptoms • Diagnosis • Disease Management Pipeline Therapeutics • Comparative Analysis Therapeutic Assessment • Assessment by Product Type • Assessment by Stage and Product Type • Assessment by Route of Administration • Assessment by Stage and Route of Administration • Assessment by Molecule Type • Assessment by Stage and Molecule Type Ocular Hypertension – DelveInsight’s Analytical Perspective In-depth Commercial Assessment • Ocular Hypertension companies’ collaborations, Licensing, Acquisition -Deal Value Trends Ocular Hypertension Collaboration Deals • Company-Company Collaborations (Licensing / Partnering) Analysis • Company-University Collaborations (Licensing / Partnering) Analysis Late Stage Products (Phase III) • Comparative Analysis NCX 470: Nicox • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Mid Stage Products (Phase II) • Comparative Analysis Sepetaprost DE-126: Santen Pharmaceutical • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Inactive Products • Comparative Analysis Ocular Hypertension Key Companies Ocular Hypertension Key Products Ocular Hypertension- Unmet Needs Ocular Hypertension- Market Drivers and Barriers Ocular Hypertension- Future Perspectives and Conclusion Ocular Hypertension Analyst Views Ocular Hypertension Key Companies Appendix
Table 1 Total Products for Ocular Hypertension Table 2 Late Stage Products Table 3 Mid Stage Products Table 4 Early Stage Products Table 5 Pre-clinical & Discovery Stage Products Table 6 Assessment by Product Type Table 7 Assessment by Stage and Product Type Table 8 Assessment by Route of Administration Table 9 Assessment by Stage and Route of Administration Table 10 Assessment by Molecule Type Table 11 Assessment by Stage and Molecule Type Table 12 Inactive Products
• Nicox • Santen Pharmaceutical • AbbVie • MediPrint Ophthalmics • Whitecap Biosciences • Ocular Therapeutix • Sylentis • Chong Kun Dang Pharmaceutical • Aerpio Pharmaceuticals
  • PRICE
  • $1500
    $4500

Our Clients